CSL abandons $3.1 billion acquisition offer for Talecris

06/9/2009 | NYTimes.com

Australian biotech company CSL dropped its $3.1 billion bid to take over Talecris Biotherapeutics because the Federal Trade Commission opposes the deal. CSL, which makes blood plasma products, will repurchase as much as 9% of its stock for about $1.3 billion and pay Talecris $75 million for ending the offer.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA